19.6%).NEW YORK, (GLOBE NEWSWIRE) - The newest report from Data Bridge Market Research, " Nephrology and Urology Devices Market" examines growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and the competitive environment in detail. The REDUCE 3 study randomized 453 patients undergoing coronary stenting and reported lower re-stenosis rates after the use of CBA than after PTCA (11.8% vs. 1 The REDUCE 2 study enrolled 416 patients and also observed a trend toward higher re-stenosis rates (52.1% vs. 27 The REDUCE 1 study enrolled 802 patients and reported slightly higher re-stenosis rates with CBA than with PTCA (32.7% vs. The RESCUT study enrolled 428 patients with ISR and reported no difference in re-stenosis between CBA (29.8%) and PTCA (31.2%). The GRT22 randomized 1238 patients and reported no difference in angiographic re-stenosis between CBA (31.4%) and PTCA (30.4%). 8, 30 Several large trials of CBA have been carried out (see Fig. 10, 16, 21, 23, 24 Other small studies evaluated CBA as pretreatment before brachytherapy for in-stent re-stenosis (ISR) and found no difference in re-stenosis rates between CBA and rotational atherectomy or between CBA and PTCA. Several small but largely positive trials of CBA, all involving less than 200 patients, reported that the use of CBA reduced re-stenosis by 41% to 69% compared with PTCA (Fig. Although atheroablative therapies may facilitate stent delivery and enhance stent expansion, the development of lower-profile, trackable, high-pressure balloon catheters ( Chapter 15) has made PTCA the default method for lesion preparation before and after coronary stenting, and in many cases no lesion preparation is required at all before stent implantation. The introduction of coronary stenting, particularly the use of drug-eluting stents (DESs Chapter 13), rapidly replaced atheroablative therapies. Evidence from randomized trials ( Table 34-1), 1, 4 – 30 however, challenged the hypothesis that routine atheroablation during PCI is beneficial. Although each device used a different mechanism for modifying thrombus or atheromatous plaque, the common goal was to obtain larger acute gains and lower re-stenosis rates than could be achieved with PTCA. Holmium laser angioplasty (HLA) premiered in 1990, and cutting balloon angioplasty (CBA) debuted in 1991. Excimer laser coronary angioplasty (ELCA), percutaneous transluminal rotational atherectomy (PTRA), and transluminal extraction coronary atherectomy (TEC) were introduced in 1988. Directional coronary atherectomy (DCA) entered clinical trials in 1987. 3 The decades-long search for a mechanical approach to excise or section atheromatous plaque emerged from the concept that plaque excision would improve clinical outcomes and lower the rate of re-stenosis after coronary intervention. 2 This was supported by angiographic analyses, which suggested that the degree of late re-stenosis was directly proportional to the gain achieved acutely during treatment and that the proportion between late loss and acute gain was consistent for a broad range of interventional devices. Before the modern era of coronary stenting, the search for treatments to overcome the limitations of PTCA was based on experimental studies, which showed that the healing response of treated coronary arteries was directly proportional to the degree of imposed injury.
0 Comments
Leave a Reply. |